U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H13ClN2O
Molecular Weight 284.74
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIAZEPAM

SMILES

CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3

InChI

InChIKey=AAOVKJBEBIDNHE-UHFFFAOYSA-N
InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3

HIDE SMILES / InChI

Molecular Formula C16H13ClN2O
Molecular Weight 284.74
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24552479

Diazepam is a benzodiazepine first discovered at Hoffman-La Roche in the late 1950s. Diazepam was approved by FDA for the treatment of anxiety disorders as well as for such conditions as skeletal muscle spasm, alcohol withdrawal syndrom and convulsions (under the most known brand Valium). The drug acts by binding to GABA-A receptors and potentiating GABA evoked current. Chronic diazepam use is associated with tolerance, dependence, and withdrawal.

Originator

Curator's Comment: # Hoffmann-La Roche

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.6 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VALIUM

Approved Use

Valium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.

Launch Date

1963
Palliative
VALIUM

Approved Use

Valium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.

Launch Date

1963
Palliative
VALIUM

Approved Use

Valium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.

Launch Date

1963
Palliative
VALIUM

Approved Use

Valium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.

Launch Date

1963
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
317 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
75 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
172 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
208 ng/mL
20 mg single, intranasal
dose: 20 mg
route of administration: intranasal
experiment type: single
co-administered:
DIAZEPAM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1530 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
330 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
779 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1227 ng*h/mL
20 mg single, intranasal
dose: 20 mg
route of administration: intranasal
experiment type: single
co-administered:
DIAZEPAM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
48 h
unknown, oral
DIAZEPAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
unknown, oral
DIAZEPAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources:
healthy, 28 years
Health Status: healthy
Age Group: 28 years
Sex: M
Sources:
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
unhealthy, 61 years
Health Status: unhealthy
Age Group: 61 years
Sex: F
Sources:
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Sources:
Other AEs: Respiratory depression, Abuse...
Other AEs:
Respiratory depression (serious|grade 5)
Abuse (serious|grade 5)
Sources:
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Disc. AE: Somnolence, Hypoventilation...
AEs leading to
discontinuation/dose reduction:
Somnolence (3 patients)
Hypoventilation (2 patients)
Rash (2 patients)
Asthenia (1 patient)
Hyperkinesia (1 patient)
Incoordination (1 patient)
Vasodilatation (1 patient)
Urticaria (1 patient)
Sources:
10 mg 2 times / day multiple, intranasal
Recommended
Dose: 10 mg, 2 times / day
Route: intranasal
Route: multiple
Dose: 10 mg, 2 times / day
Co-administed with::
benzodiazepines
Sources:
unhealthy, adult
Other AEs: Respiratory depression...
Other AEs:
Respiratory depression (serious|grade 5)
Sources:
10 mg 4 times / day multiple, intramuscular
Recommended
Dose: 10 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 10 mg, 4 times / day
Co-administed with::
benzodiazepines
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: anxiety disorders
Age Group: adult
Sources:
Other AEs: Respiratory depression, Abuse...
Other AEs:
Respiratory depression (serious|grade 5)
Abuse (serious|grade 5)
Sources:
10 mg 4 times / day multiple, oral
Recommended
Dose: 10 mg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg, 4 times / day
Co-administed with::
OPIOIDS
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anxiety Disorders
Age Group: adult
Sources:
Other AEs: Respiratory depression...
Other AEs:
Respiratory depression (serious|grade 5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Abuse serious|grade 5
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Sources:
Respiratory depression serious|grade 5
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Sources:
Asthenia 1 patient
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Hyperkinesia 1 patient
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Incoordination 1 patient
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Urticaria 1 patient
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Vasodilatation 1 patient
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Hypoventilation 2 patients
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Rash 2 patients
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Somnolence 3 patients
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Respiratory depression serious|grade 5
10 mg 2 times / day multiple, intranasal
Recommended
Dose: 10 mg, 2 times / day
Route: intranasal
Route: multiple
Dose: 10 mg, 2 times / day
Co-administed with::
benzodiazepines
Sources:
unhealthy, adult
Abuse serious|grade 5
10 mg 4 times / day multiple, intramuscular
Recommended
Dose: 10 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 10 mg, 4 times / day
Co-administed with::
benzodiazepines
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: anxiety disorders
Age Group: adult
Sources:
Respiratory depression serious|grade 5
10 mg 4 times / day multiple, intramuscular
Recommended
Dose: 10 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 10 mg, 4 times / day
Co-administed with::
benzodiazepines
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: anxiety disorders
Age Group: adult
Sources:
Respiratory depression serious|grade 5
10 mg 4 times / day multiple, oral
Recommended
Dose: 10 mg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg, 4 times / day
Co-administed with::
OPIOIDS
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anxiety Disorders
Age Group: adult
Sources:
OverviewDrug as perpetrator​Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
Letter: Clonazepam in the treatment of drug-induced dyskinesia.
1975 Feb 1
[The mechanism of the anticonvulsive action of diazepam].
1975 Mar
Influence of adenosine agonists and antiepileptic drugs on theophylline-induced seizures in rats.
1998 Oct
Distinct features of seizures induced by cocaine and amphetamine analogs.
1999 Jul 21
[A case of cardiac arrest after torsades de pointes due to prolonged QT interval syndrome possibly associated with subarachnoid hemorrhage].
1999 Jun
Severe vasculitis after therapy with diazepam.
1999 Jun
Involvement of nitric oxide and nitric oxide synthase activity in anticonvulsive action.
1999 Mar 1
Effects of L-arginine on picrotoxin-induced increase in brain ammonia concentrations and convulsions in rats.
1999 Oct
Seizures caused by possible interaction between olanzapine and clomipramine.
2000 Apr
Effects of anticonvulsants on local anaesthetic-induced neurotoxicity in rats.
2000 Feb
Manic episode in an ifosfamide-treated patient.
2000 Jan-Feb
Chronic cocaine differentially affects diazepam's anxiolytic and anticonvulsant actions. Relationship to GABA(A) receptor subunit expression.
2000 Nov 3
Flumazenil prevents diazepam-elicited anticonvulsant action and concomitant attenuation of glutamate overflow.
2000 Oct 27
Regional and subunit-specific downregulation of acid-sensing ion channels in the pilocarpine model of epilepsy.
2001 Feb
Diazepam in the treatment of GHB dependence.
2001 Feb
[Febrile convulsions, Treatment and prognosis].
2001 Feb 19
Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist.
2001 Feb 2
Effects of a novel uncompetitive NMDA receptor antagonist, MRZ 2/579 on ethanol self-administration and ethanol withdrawal seizures in the rat.
2001 Feb 9
[Anesthesia for a patient with cardiac sarcoidosis].
2001 Jan
[Effect of diazepam on apnea attacks in a 6-year-old girl with Rett syndrome: a polysomnographic study].
2001 Jan
Radial entrapment neuropathy due to chronic injection-induced triceps fibrosis.
2001 Jan
Effects of antiepileptic drugs on rat platelet aggregation: ex vivo and in vitro study.
2001 Jan
Intranasal midazolam for treating febrile seizures in children. Buccal midazolam for childhood seizures at home preferred to rectal diazepam.
2001 Jan 13
Topical anesthesia for cataract surgery: a population-based perspective.
2001 Mar
A behavioral economic analysis of polydrug abuse in alcoholics: asymmetrical substitution of alcohol and cocaine.
2001 Mar 1
Female gastrin-releasing peptide receptor (GRP-R)-deficient mice exhibit altered social preference for male conspecifics: implications for GRP/GRP-R modulation of GABAergic function.
2001 Mar 16
Targeted disruption of the GABA(A) receptor delta subunit gene leads to an up-regulation of gamma 2 subunit-containing receptors in cerebellar granule cells.
2001 Mar 30
Patents

Sample Use Guides

Tale 2-10 mg, 2 to 4 times daily.
Route of Administration: Oral
In Vitro Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/6722533
Rat brain membranes were treated with diazepam (1-1000 nM) and the drug was shown to enhance the effects of iontophoretically applied GABA.
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:05:32 GMT 2023
Edited
by admin
on Sat Dec 16 17:05:32 GMT 2023
Record UNII
Q3JTX2Q7TU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIAZEPAM
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
INN   USAN  
Official Name English
VALTOCO
Brand Name English
RO 5-2807
Code English
DIAZEPAM [VANDF]
Common Name English
ANSIOLISINA
Common Name English
DIAZEPAM CIV
USP-RS  
Common Name English
VALIUM
Brand Name English
LA-III
Code English
DIAZEPAM [GREEN BOOK]
Common Name English
DIZAC
Brand Name English
SERVIZEPAM
Common Name English
DIAZEPAM [IARC]
Common Name English
RO-5-2807
Code English
DIAZEPAM [USAN]
Common Name English
DIASTAT
Brand Name English
NSC-77518
Code English
LA III
Code English
2H-1,4-BENZODIAZEPIN-2-ONE, 7-CHLORO-1,3-DIHYDRO-1-METHYL-5-PHENYL-
Systematic Name English
NSC-169897
Code English
DIAZEPAM [ORANGE BOOK]
Common Name English
RO-52807
Code English
7-CHLORO-1-METHYL-5-PHENYL-3H-1,4-BENZODIAZEPIN-2(1H)-ONE
Systematic Name English
DIAZEPAM [HSDB]
Common Name English
WY-3467
Code English
METHYL DIAZEPINONE
Systematic Name English
CENTRAZEPAM
Common Name English
Q-PAM
Brand Name English
7-CHLORO-1,3-DIHYDRO-1-METHYL-5-PHENYL-2H-1,4-BENZODIAZEPINE-2-ONE
Systematic Name English
VALRELEASE
Brand Name English
DIAZEPAM [MART.]
Common Name English
DIACEPIN
Common Name English
Diazepam [WHO-DD]
Common Name English
DIAZEPAM [MI]
Common Name English
diazepam [INN]
Common Name English
DIAZEPAM [USP MONOGRAPH]
Common Name English
DIAZEPAM [JAN]
Common Name English
NRL-1
Code English
DIAZEPAM [EP MONOGRAPH]
Common Name English
DIAZEPAM CIV [USP-RS]
Common Name English
7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
Systematic Name English
TRANQUASE
Common Name English
Classification Tree Code System Code
NDF-RT N0000007542
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 384112
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
EPA PESTICIDE CODE 600069
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 334911
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 518316
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 8.4
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
LIVERTOX NBK548352
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
WHO-VATC QN05BA01
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 543516
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 638118
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 24.3
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 382512
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
WHO-ATC N05BA01
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 05
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
DEA NO. 2765
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
NCI_THESAURUS C1012
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 61591
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
NDF-RT N0000175694
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1185008
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
MERCK INDEX
m4267
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY Merck Index
NSC
169897
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
RXCUI
3322
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY RxNorm
MESH
D003975
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
HSDB
3057
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
LACTMED
Diazepam
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
DRUG BANK
DB00829
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
EPA CompTox
DTXSID4020406
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
DRUG CENTRAL
852
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
WIKIPEDIA
DIAZEPAM
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
EVMPD
SUB07069MIG
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
IUPHAR
3364
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
FDA UNII
Q3JTX2Q7TU
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
NCI_THESAURUS
C28982
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
INN
1295
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
CAS
439-14-5
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
PUBCHEM
3016
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
ChEMBL
CHEMBL12
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
CHEBI
49575
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
ECHA (EC/EINECS)
207-122-5
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
SMS_ID
100000092362
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
DAILYMED
Q3JTX2Q7TU
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
NSC
77518
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DIAZEPAM
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Very slightly soluble in water; soluble in ethanol (~750 g/l) TS. Category: Tranquillizer. Storage: Diazepam should be kept in a well-closed container, protected from light. Definition: Diazepam contains not less than 99.0% and not more than 101.0% of C16H13ClN2O, calculated with reference to the dried substance.
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE TOXIC -> PARENT
Metabolite produces adverse autonomic nervous symptoms in man.
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
pKa CHEMICAL
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC IV: 8 minutes

IM: 1.31 hours (SYRINGE)

IM: 1.47 hours (AUTOINJECTOR)

EFFECT OF FOOD: DELAYED Tmax

RECTAL GEL: 1.5 hours

PROTEIN BINDING PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC IV: 15-21 HOURS (CHILD 2-12 YEARS)

IV: 40-50 HOURS (INFANT AND TODDLER 1 MONTH TO 2 YEARS)

IV: 18-20 HOURS (ADOLESCENT 12-16 YEARS)

IV: 50-95 HOURS (NEONATE, BIRTH UP TO 1 MONTH)

IV: ABOUT 100 HOURS (ELDERLY 95 YEARS)

IV: ABOUT 15 HOURS (YOUNG ADULT 18 YEARS)

PREMATURE INFANTS, 28-34 WEEKS GESTATIONAL AGE AND 8-81 DAYS POSTPARTUM: 54 HOURS

DESMETHYLDIAZEPAM: UP TO 100 HOURS

GERIATRICS: INCREASES BY ABOUT 1 HOUR FOR EACH YEAR OF AGE BEGINNING WITH A HALF-LIFE OF 20 HOURS AT 20 YEARS OF AGE

CHILDREN 3-8 YEARS: 18 HOURS

FULL TERM INFANTS: 30 HOURS

MAXIMUM TOLERATED DOSE TOXICITY SEDATION, ENDOSCOPIC PROCEDURE: 20 mg IV IMMEDIATELY PRIOR TO PROCEDURE

SEVERE, RECURRENT SEIZURE: 30 mg/dose IV

ORAL BIOAVAILABILITY PHARMACOKINETIC
BIOAVAILABILTY PHARMACOKINETIC